SEC Comment Letter 0000000000-26-004634 to GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc.
Date: May 6, 2026 · CIK: 0000109657 · Accession: 0000000000-26-004634
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295461
Letter
May 6, 2026 Michael Breen Chief Executive Officer GT Biopharma, Inc. 505 Montgomery Street, 10th Floor San Francisco, California 94111 Re: GT Biopharma, Inc. Registration Statement on Form S-1 Filed April 30, 2026 File No. 333-295461 Dear Michael Breen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alan A. Lanis, Jr.
Show Raw Text
May 6, 2026 Michael Breen Chief Executive Officer GT Biopharma, Inc. 505 Montgomery Street, 10th Floor San Francisco, California 94111 Re: GT Biopharma, Inc. Registration Statement on Form S-1 Filed April 30, 2026 File No. 333-295461 Dear Michael Breen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alan A. Lanis, Jr.